Evofem Biosciences, Inc. (EVFM)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.01
- As of
Kresmion compiles this page from EVFM's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Evofem Biosciences, Inc. (EVFM): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-15.
See the full EVFM dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for EVFM on one page. Preview it with sample data, then open it live with a free account.
Preview the EVFM dossierActive events for EVFM
- mediumEarnings below estimates
Q4-2022: Missed consensus by 44.7% - EPS $-38.75 vs $-26.775 estimate
- mediumEarnings below estimates
Missed consensus by 44.7% - EPS $-38.75 vs $-26.775 estimate
- mediumEarnings above estimates
Q3-2023: Beat consensus by 263.4% - EPS $0.1 vs $-0.0612 estimate
- mediumEarnings above estimates
Q4-2023: Beat consensus by 29.3% - EPS $-0.44 vs $-0.6222 estimate
FREE, NO ACCOUNT
Every event on EVFM, as it fires
New filings, 13F moves and cross asset events on EVFM land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter.
Recent SEC filings, EVFM
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
EVFM's 10-Q filed Aug 14, 2026 states:
…and otherwise succeed in its future operations raise substantial doubt about the Company's ability to continue as a going concern.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on EVFM
EVFM against its peers
EVFM's operating margin of 16.7% ranks in the 95th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-06-30.
| Metric | EVFM | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 20.2M USD | 1.3M USD | 95 | 9 |
| Gross margin | 77.1% | 8.4% | 92 | 5 |
| Operating margin | 16.7% | -869.3% | 95 | 9 |
| Net margin | 1.9% | -862.3% | 95 | 9 |
| Return on equity | n/a | -106.4% | n/a | 11 |
Peers (18): LNAI, ADTX, PTIX, CDT, ARTL, VRAX, VBIO, CPMV, SCNI, MTNB, ISCO, BDRX, AGTX, ATXI, RMTG, OGEN, GOVX, KAPA. Left out: MLEC (period gap), AXIM (period gap), BBLG (no annual filing), CLSDQ.D (no annual filing), ELAB (no annual filing), LABT (no annual filing), CYTOF (period gap). Fiscal periods ending between 2025-03-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (EVFM: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in EVFM on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on EVFM in the last 180 days.
Upstream: SEC EDGAR filings for EVFM
Kresmion, "Evofem Biosciences, Inc. (EVFM) institutional holdings and SEC filings", data as of 2026-10-15, https://kresmion.com/research/EVFM. Upstream data: SEC EDGAR filings for EVFM.
Link to this data (HTML):
<a href="https://kresmion.com/research/EVFM">Evofem Biosciences, Inc. (EVFM) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow EVFM on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to EVFM for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.